Coronavirus Notebook: Middle Ground Pricing As Moderna Reaches 100m Dose US Agreement
Plus, Evidence Accelerator Finds No Benefit With HCQ
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.
